Reviewed by Christian Espinosa, MBA, CISSP · Founder & CEO
Published April 2026 · Last reviewed May 2026
The Med Device Cyber Podcast · with Rob Bedford · April 10, 2026 This episode of The Med Device Cyber Podcast features Rob Bedford, CEO of Franklyn Health, discussing the critical role of Contract Research Organizations (CROs) in medical device development. The conversation highlights the unique challenges faced by small MedTech startups, especially concerning budget constraints, speed to market, and the need for specialized expertise in clinical research. Rob explains how Franklyn Health caters specifically to these smaller entities, offering cost-effective and agile solutions for navigating clinical trials. The discussion delves into the phased approach of clinical studies, from preclinical animal studies to first-in-human and pivotal trials, emphasizing the distinct pathways for medical devices compared to pharmaceuticals. A significant portion of the episode is dedicated to the integration of cybersecurity in the product development lifecycle. The speakers stress the importance of "security by design," advocating for early consideration of cybersecurity to avoid costly and time-consuming retrofits. They explore the implications of design changes on clinical data validation and the potential for a "quicksand" effect if cybersecurity is not baked in from the outset. Further, the episode addresses the allocation of responsibility and accountability in data protection during clinical trials, clarifying the roles of manufacturers, CROs, and principal investigators. The FDA's Q-submission process is lauded as an underutilized resource for early feedback, and the challenges of patient enrollment and ensuring diversity in clinical trials are also explored. The episode concludes with a strong emphasis on early planning and a reverse-engineering approach to regulatory and commercialization strategies, particularly when aiming for global markets given varying cybersecurity and clinical trial requirements.
Key Takeaways
- Small MedTech startups face unique challenges in clinical trials, including budget limitations and the need for rapid development, making specialized CROs essential.
- Integrating cybersecurity into medical devices from the initial design phase is crucial to prevent "quicksand" scenarios, where retrofitting security later can invalidate clinical data and significantly delay market entry.
- Accountability for patient data security in clinical trials ultimately rests with the device manufacturer (sponsor), regardless of delegated responsibilities to CROs or clinical sites.
- The FDA's Q-submission process is a valuable, and often underutilized, tool for gaining early feedback on regulatory and clinical strategies, significantly de-risking product development.
- Planning ahead by understanding target markets and their respective regulatory and cybersecurity requirements (e.g., FDA requirements for US patient data in clinical trials) is vital for successful global commercialization.
- Enrollment is the greatest challenge in clinical trials, especially for rare conditions, often requiring more sites and can lead to study failures if not addressed effectively.
Listen on mdcpodcast.com · Watch on YouTube
Listen to this episode
Want help applying this to your own device program?
Blue Goat Cyber is a specialist medical device cybersecurity firm: 250+ FDA submissions, zero rejections. If anything in this conversation hit close to home, book a 30-minute strategy session - no cost, no obligation.